New study highlights potential cost savings when using yttrium-90 glass microspheres for treatment of hepatocellular carcinoma
TARE (transarterial radio-embolization) using yttrium-90 glass microspheres, associated with both cost savings and overall decreased use of hospital resource
WASHINGTON D.C., US: BTG plc (LSE: BTG), an international specialist healthcare company, has today announced the publication of new data at the 21st Annual Meeting of ISPOR (International Society for Pharmacoeconomics and Outcomes Research), highlighting that treatment of hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres is associated with cost savings and decreased hospital resource use.
The results of the budget impact analysis, undertaken from a Canadian hospital perspective, show that for a Canadian hospital managing 200 HCC patients annually, reimbursing TARE (transarterial radio-embolization) would incur savings of approximately $37,000, $55,000 and $75,000 in years one, two and three respectively. In year three, the analysis includes incremental costs of $207,000 for device acquisition compared against savings of $281,000 for administration and savings of $1,000 in adverse event management.
Commenting on the results, study author Marie Maxime Hubert, from JSS Medical Research Inc., said, “For patients with HCC, at either intermediate or advanced stages, TARE has the potential to improve survival, has a favorable safety profile and has seen successful outcomes in patients with portal vein thrombosis (PVT). In the context of increasingly cost-pressured health systems around the world, the potential for TARE to improve patient outcomes while at the same time support hospitals’ management of scarce resources should not be underestimated.”
The budget impact analysis applied for the study used the Ontario Case Costing Initiative database, published literature and expert opinion to determine the potential for cost savings from a Canadian hospital perspective. It compared the treatment of intermediate HCC with TARE using yttrium-90 glass microspheres, versus TACE, an inpatient procedure, including cTACE and drug-eluting beads TACE (DEB-TACE). In patients with advanced HCC, TARE was compared to self-administered sorafenib.
About BTG Interventional Medicine
BTG Interventional Medicine is part of BTG plc, a growing international specialist healthcare company. As medicine moves from major surgery to minor procedure, from the systemic to the local, no company endeavors to do more than BTG Interventional Medicine to help doctors in their quest to see more, reach further and treat smarter. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots, and varicose veins. To learn more about BTG Interventional Medicine, please visit: btg-im.com.
TheraSphere® 90Y glass microspheres are specifically engineered to carry far greater power than any other 90Y liver-directed cancer therapy, delivering high doses of radiation to liver tumors while sparing normal tissue. The result is a powerful, targeted and well-tolerated therapy that may lead to patients becoming eligible for curative therapies.
In the US, TheraSphere® is FDA approved under a Humanitarian Device Exemption (HDE) for the treatment of hepatocellular carcinoma (HCC). In the EU, TheraSphere® is CE Marked for the treatment of hepatic neoplasia. In Canada, TheraSphere® may be used in the treatment of hepatic neoplasia in patients who have appropriately positioned arterial catheters.
For full instructions for use and important safety information, please visit www.therasphere.com.
For further information contact:
Chris Sampson, Corporate Communications Director
+44 20 7575 1595; Mobile: +44 7773 251 178
+44 208 618 2755; Mobile: +44 7725 925 841
Media Liaison – US
+1 202 828 5073; Mobile: +1 202 577 5847